TherapeuticsMD (NASDAQ:TXMD) had its price objective decreased by research analysts at Oppenheimer from $13.00 to $10.00 in a report released on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective would indicate a potential upside of 320.17% from the stock’s previous close.

A number of other brokerages have also issued reports on TXMD. ValuEngine upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Thursday, February 28th. BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. restated a “buy” rating and issued a $14.00 price target on shares of TherapeuticsMD in a research note on Tuesday, February 12th. Finally, Noble Financial restated an “outperform” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research note on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.16.

Shares of TXMD traded down $0.63 during mid-day trading on Tuesday, reaching $2.38. 18,707,283 shares of the stock traded hands, compared to its average volume of 3,187,358. The firm has a market capitalization of $759.85 million, a P/E ratio of -4.03 and a beta of 2.14. TherapeuticsMD has a 12-month low of $2.21 and a 12-month high of $7.42. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. The company had revenue of $3.95 million for the quarter, compared to analyst estimates of $5.96 million. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) earnings per share. Equities analysts expect that TherapeuticsMD will post -0.64 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of TXMD. Bank of New York Mellon Corp increased its stake in TherapeuticsMD by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 30,499,363 shares of the company’s stock valued at $116,202,000 after purchasing an additional 213,444 shares during the last quarter. JPMorgan Chase & Co. increased its stake in TherapeuticsMD by 3.0% during the first quarter. JPMorgan Chase & Co. now owns 20,435,672 shares of the company’s stock valued at $99,521,000 after purchasing an additional 601,899 shares during the last quarter. FMR LLC increased its stake in TherapeuticsMD by 0.5% during the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after purchasing an additional 89,870 shares during the last quarter. BlackRock Inc. increased its stake in TherapeuticsMD by 3.8% during the fourth quarter. BlackRock Inc. now owns 16,687,563 shares of the company’s stock valued at $63,579,000 after purchasing an additional 616,994 shares during the last quarter. Finally, Daruma Capital Management LLC increased its stake in TherapeuticsMD by 11.8% during the first quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock valued at $34,631,000 after purchasing an additional 750,235 shares during the last quarter. Institutional investors and hedge funds own 78.93% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: What is the CBOE Russell 2000® Volatility Index?

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.